Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2024 09:38 ET | Source: Spherix Global Insights

Tremfya's Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights

EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment...
November 07, 2024 17:09 ET | Source: Spherix Global Insights

Spherix Global Insights Focuses on Earlier use of Advanced Treatments in Hidradenitis Suppurativa (HS) as a Catalyst for Better Patient Outcomes

EXTON, PA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights has published a new white paper, Earlier Diagnosis and Treatment: The Key to Better Outcomes in Hidradenitis Suppurativa,...
November 01, 2024 09:17 ET | Source: Spherix Global Insights

Critical Gaps in FSGS Treatment Highlight Need for New Therapies, with Pipeline Assets from Travere, Vertex, and Dimerix Poised to Address Unmet Needs

EXTON, PA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Focal segmental glomerulosclerosis (FSGS), one of the most common glomerular diseases seen by nephrologists, ranks among the top three rare kidney...
October 18, 2024 10:56 ET | Source: Spherix Global Insights

US Rheumatologists and Dermatologists Report Over Half of their Dermatomyositis Patients Not Optimally Managed, According to Spherix Global Insights

EXTON, PA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Dermatomyositis (DM) is a rare inflammatory disease characterized by muscle weakness and a distinctive skin rash. Currently, the standard of care...
October 16, 2024 14:48 ET | Source: Spherix Global Insights

Shifts in the Psoriasis Market Suggest Strong Potential for Emerging Oral Therapies

EXTON, PA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biologics have long been the cornerstone of psoriasis (PsO) treatment, valued for their proven efficacy and safety. However, the growing demand for...
October 14, 2024 12:33 ET | Source: Spherix Global Insights

Hemophilia Markets Poised for Evolution as Competitive Dynamics between Hemlibra (Roche/Genentech) and Altuviiio (Sanofi) Intensify and Hympavzi (Pfizer) Receives Approval, According to Spherix Global Insights

EXTON, PA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Hemophilia, a genetic disorder that impairs blood clotting, affects thousands of people worldwide. The treatment landscape is rapidly evolving, fueled by...
October 10, 2024 10:28 ET | Source: Spherix Global Insights

Roche/Genentech’s Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results

EXTON, PA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a...
October 02, 2024 12:27 ET | Source: Spherix Global Insights

US Rheumatologists Identify BAFF-R Inhibitors as the Most Promising Treatment Approach for Sjögren’s Disease, According to Spherix Global Insights

EXTON, PA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Sjögren’s disease is a systemic autoimmune rheumatic condition that can profoundly affect a patient's overall functioning. Common symptoms include...
October 01, 2024 10:51 ET | Source: Spherix Global Insights

Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June

EXTON, PA, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The past twelve months have been transformative for the rapidly evolving ulcerative colitis (UC) market, with a surge in advanced therapies receiving FDA...
September 25, 2024 08:16 ET | Source: Spherix Global Insights

Spherix Global Insights Expands into Financial Services, Empowering Asset Managers and Hedge Funds with Critical Pharmaceutical Market Insights

EXTON, PA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm, is expanding its specialized offerings to buy-side financial firms...